title: Budesonide added to modified porcine surfactant Curosurf may additionally improve the lung functions in meconium aspiration syndrome.
abstract: Severe meconium aspiration syndrome (MAS) in newborns is often treated by exogenous surfactant. Because its efficacy is reduced by meconium-induced inflammation, glucocorticoid budesonide was added into surfactant preparation Curosurf to enhance efficacy of the surfactant therapy in experimental model of MAS. Oxygen-ventilated rabbits were intratracheally given meconium (25 mg/ml, 4 ml/kg) to induce respiratory failure. Thirty minutes later, animals were treated by intratracheal budesonide (0.25 mg/kg) or surfactant lung lavage (10 ml/kg, 5 mg phospholipids/ml) repeated twice, followed by undiluted Curosurf (100 mg phospholipids/kg) or by the above mentioned surfactant treatment with the last surfactant dose fortified with budesonide (0.25 mg/kg) or were untreated. Animals were ventilated for additional 5 hours and respiratory parameters were measured regularly. After sacrificing animals, wet-dry lung weight ratio was evaluated and plasma levels of interleukins (IL)-1beta, -6, -8, and TNF-alpha were measured by ELISA method. Efficacy of the given therapies to enhance lung functions and to diminish lung edema formation and inflammation increased from budesonide-only and surfactant-only therapy to surfactant+budesonide therapy. Combined therapy improved gas exchange from 30 min of administration, and showed a longer-lasting effect than surfactant-only therapy. In conclusions, budesonide additionally improved the effects of exogenous surfactant in experimental MAS.
authors: Department of Physiology, Jessenius Faculty of Medicine, Comenius University, Martin, Slovakia. p.mikolka@gmail.com.
authors: P
authors: P
authors: Mikolka
authors: D
authors: D
authors: Mokrá
authors: J
authors: J
authors: Kopincová
authors: L
authors: L
authors: Tomčíková-Mikušiaková
authors: A
authors: A
authors: Calkovská
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001688:Biological Products / Q000008:administration & dosage*; D001993:Bronchodilator Agents / Q000008:administration & dosage; D019819:Budesonide / Q000008:administration & dosage*; D004338:Drug Combinations; D004357:Drug Synergism; D005260:Female; D007155:Immunologic Factors / Q000378:metabolism*; D008297:Male; D008471:Meconium Aspiration Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology*; D010743:Phospholipids / Q000008:administration & dosage*; D011663:Pulmonary Surfactants; D011817:Rabbits; D015656:Respiratory Mechanics / Q000187:drug effects*; D013552:Swine; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D001688:Biological Products; D001993:Bronchodilator Agents; D004338:Drug Combinations; D007155:Immunologic Factors; D010743:Phospholipids; D011663:Pulmonary Surfactants; D019819:Budesonide; C068291:poractant alfa